Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Obesity Treatments Regulatory Approval FDA Approval Oncology FDA Approvals Lenacapavir Bepirovirsen Weight Loss Drugs Nanobody Technology FDA Regulations

BioCryst Cuts Internal Discovery After Q2 ORLADEYO Gains and Pediatric Rollout

The move is meant to lower R&D costs, preserve cash, and shift future innovation to external partners as late-stage trials continue.

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

GSK Reports Q2 Beat and Unveils £1.9 Billion Savings Plan

AstraZeneca Beats Q2 Estimates and Reaffirms 2026 Guidance

Novartis Returns to Sales Growth as New Drugs Offset Entresto Slump

Kalshi Opens Betting Markets for Phase 3 Drug Trials and FDA Decisions

Sinopia’s SB-0110 Boosts Levodopa Benefit and Cuts Dyskinesia in Animal Models

Wegovy Pill Arrives in UK Private Market as Clinicians Flag Dosing and Safety Risks

HSE Refers Skyclarys Reimbursement to Rare Diseases Review Committee

Fulcrum Halts Pociredir Development After FDA Flags PRC2 Cancer Risk

New Hepatitis B Drug Produces Functional Cure in About One in Five Patients

Bepirovirsen Achieves Functional Cure in About One in Five People With Chronic Hepatitis B

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Cormedix Lifts 2026 Outlook After Q1 Beat, Sets H2 FDA Filing Plan for Rizzeo

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Design

Lilly Launches First Amyloid-Targeting Alzheimer’s Drug in India at Rs 91,688 a Dose

Milestone Posts Q1 Loss as CARDAMYST Launch Shows Early Uptake and AFib-RVR Phase 3 Begins

Capricor Outlines Daramyocell’s FDA Review and Launch Prep as Distributor Dispute Looms

UNAM Scientists Turn Scorpion Venom and Habanero Chili Into Experimental Antibiotics

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut